Background and Aim: Lipoprotein-associated phospholipase A2(Lp-PLA2) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol and a higher prevalence of early CVD. Our aim was to evaluate the differences in Lp-PLA2activity in a population of hypercholesterolemic patients with and without definite FH. Methods and Results: Hypercholesterolemic patients were consecutively recruited. Definite FH was defined according to Dutch Lipid Clinic Network criteria â¥8. All patients underwent routine clinical examination and biological assessments and Lp-PLA2activity was measured in blood samples. Among 469 patients, 118 had a definite diagnosis of FH. Lp-PLA2activity was significantly higher in definite FH patients compared to non-definite FH patients (206.5 Â± 54.5 vs. 180.8 Â± 48.4 nmol/min/mL, p < 0.0001). Lp-PLA2positively correlated with total cholesterol, LDL-C and apolipoprotein B and negatively with HDL-C and apolipoprotein A-1. In multivariate analysis, definite FH diagnosis, LDL-C, HDL-C and statin treatment remained correlates of Lp-PLA2independently of systolic blood pressure. Conclusions: Lp-PLA2activity was higher in definite FH than in non-definite FH patients independently of LDL-C levels and statin treatment. These results highlight the particular phenotype of FH subjects among hypercholesterolemic patients. As increased Lp-PLA2activity suggests, FH patients exhibit higher arterial inflammation that may contribute to their high cardiovascular risk. Our results reinforce the potential beneficial role of statins pleiotropic effects and the need for proper identification and treatment of FH patients.
|Numero di pagine||7|
|Rivista||NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES|
|Stato di pubblicazione||Published - 2018|
All Science Journal Classification (ASJC) codes